Mergers & Acquisitions - USA

Filter

Current filters:

USA

Popular Filters

Hikma to take over Boehringer’s Ben Venue manufacturing site

24-07-2014

Jordan-based drugmaker Hikma Pharmaceuticals says it has agreed with Ben Venue Laboratories, part of…

Ben Venue LabsBoehringer IngelheimGenericsHikma PharmaceuticalsMergers & AcquisitionsProductionUSA

Shire finally accepts AbbVie’s takeover offer

Shire finally accepts AbbVie’s takeover offer

18-07-2014

After a protracted and at times hostile courtship, Ireland-headquartered drugmaker Shire has finally…

AbbVieHumiraMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Shire succumbs to AbbVie’s yet again increased offer of £53.20 per share

Shire succumbs to AbbVie’s yet again increased offer of £53.20 per share

14-07-2014

Ireland-headquartered Shire, which just on Friday confirmed it had finally entered talks with suitor…

AbbVieAdalimumabFinancialIrelandMergers & AcquisitionsPharmaceuticalShireUSA

Shire confirms it has entered into talks with AbbVie

Shire confirms it has entered into talks with AbbVie

12-07-2014

Following reports by the Bloomberg news service, on Friday Ireland-based drugmaker Shire confirmed that…

AbbVieIrelandMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Baxter buys AesRx, gaining rights to investigational SCD drug

Baxter buys AesRx, gaining rights to investigational SCD drug

10-07-2014

US drugmaker Baxter International said yesterday that it has acquired AesRx, a private US biopharmaceutical…

Aes-103AesRxBaxter InternationalBiotechnologyHematologyMergers & AcquisitionsRare diseasesUSA

MabVax Therapeutics and Telik close merger

MabVax Therapeutics and Telik close merger

09-07-2014

USA-based MabVax Therapeutics, a privately held cancer immunotherapy company, and Telik, a publicly-traded…

MabVax TherapeuticsMergers & AcquisitionsOncologyPharmaceuticalTelikUSA

Transcept and Paratek join forces in reverse takeover

Transcept and Paratek join forces in reverse takeover

01-07-2014

US pharma company Transcept Pharmaceuticals and privately-held biopharmaceutical company Paratek Pharmaceuticals…

Antibiotics and Infectious diseasesMergers & AcquisitionsParatek PharmaceuticalsPharmaceuticalTranscept PharmaUSA

Allergan rejects Valeant’s latest bid

Allergan rejects Valeant’s latest bid

24-06-2014

Botox maker Allergan has announced that its Board of Directors has unanimously determined that Valeant…

AllerganBusiness FinanceBusiness FinanceEconomicsFinanceMergers & AcquisitionsPharmaceuticalStock marketUSAValeant Pharmaceuticals

FTC approves final order on Akorn’s acquisition of Hi-Tech

FTC approves final order on Akorn’s acquisition of Hi-Tech

22-06-2014

Following a public comment period, the US Federal Trade Commission on Friday approved a final order settling…

AkornGenericsHi-Tech PharmacalMergers & AcquisitionsUSAValeant Pharmaceuticals International

Forest appeases shareholders over Actavis deal

30-05-2014

US drugmaker Forest Laboratories has reached a settlement with shareholders over its deal with generics…

ActavisBusinessBusiness FinanceEnvironmentForest LaboratoriesMajorMergers & AcquisitionsNew York Stock ExchangePharmaceuticalUSA

Hikma to buy Boehringer’s Bedford Labs unit for $300 million

Hikma to buy Boehringer’s Bedford Labs unit for $300 million

28-05-2014

Jordon-based drugmaker Hikma Pharmaceuticals has signed an asset purchase agreement with Ben Venue Laboratories,…

Bedford LaboratoriesBoehringer IngelheimGenericsHikma PharmaceuticalsMergers & AcquisitionsUSA

Sun Pharma vows “appropriate action” as Ranbaxy merger halted

05-05-2014

In the wake of a suspension of its proposed $4 billion acquisition of domestic rival Ranbaxy Laboratories…

GenericsIndiaMergers & AcquisitionsProductionRanbaxy LaboratoriesSun Pharmaceutical IndustriesUSA

SI Group acquires ibuprofen and antioxidants from Albemarle Corp

SI Group acquires ibuprofen and antioxidants from Albemarle Corp

17-04-2014

Family-owned US chemical developer and manufacturer SI Group has signed a deal to acquire the antioxidants,…

AlbemarleAnalgesiaibuprofenMergers & AcquisitionsPharmaceuticalUSA

FTC imposes conditions on Akorn’s proposed buy of Hi-Tech Pharmacal

15-04-2014

In order to consummate the proposed $640 million acquisition of Hi-Tech Pharmacal by fellow USA-based…

ActavisAkornGenericsHi-Tech PharmacalMergers & AcquisitionsNorth AmericaUSA

US regulator calls for divestment for Endo Health’s acquisition of Boca Pharmacal to proceed

US regulator calls for divestment for Endo Health’s acquisition of Boca Pharmacal to proceed

02-02-2014

US specialty health care firm Endo Health Solutions and its takeover target generic drugmaker Boca Pharmacal…

Boca PharmacalEndo Health SolutionsGenericsMergers & AcquisitionsNorth AmericaRegulationUSA

Medigene’s buy of Trianta is “lucrative move” say analysts

31-01-2014

Medigene’s 4 million euro ($5.5 million) purchase of fellow German company Trianta Immunotherapies…

FinancialImmunologicalsMedigeneMergers & AcquisitionsOncologyPharmaceuticalTrianta ImmunotherapiesUSA

Fluidigm and DVS Sciences announce merger worth $207.5 million

30-01-2014

US-based microfluidic systems developer Fluidigm Corporation (NASDAQ:FLDM) has entered into a definitive…

BiotechnologyMergers & AcquisitionsUSA

Genesis 2013: Astex Pharma’s journey from biotech start-up to $886m success story

Genesis 2013: Astex Pharma’s journey from biotech start-up to $886m success story

16-12-2013

A biotech company’s dream 14-year journey from small start-up to an $886 million takeover bid provided…

Asia-PacificAstex PharmaceuticalsBiotechnologyFinancialInterviewsMergers & AcquisitionsOtsukaUKUSA

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

Genesis 2013: Secrets of B-MS and AstraZeneca Amylin deal revealed

16-12-2013

Secrets of how Bristol-Myers Squibb and AstraZeneca arranged a behind-the-scenes deal to buy Amylin were…

AmylinAstraZenecaBristol-Myers SquibbDiabetesInterviewsLegalMergers & AcquisitionsPharmaceuticalUKUSA

Report: Life science companies experience IPO slowdown

10-12-2013

Life sciences companies have been completing fewer initial public offerings (IPOs) this season as the…

Mergers & AcquisitionsPharmaceuticalRocheSalix PharmaceuticalsShireUSA

Shire’s acquisition of ViroPharma will add $831m in revenue by 2018, says GlobalData

Shire’s acquisition of ViroPharma will add $831m in revenue by 2018, says GlobalData

19-11-2013

Ireland-based drugmaker Shire’s (LSE: SHP) buy-out of US orphan drug company ViroPharma (Nasdaq: VPHM)…

CinryzeEuropeFinancialMergers & AcquisitionsPharmaceuticalShireUSAViroPharma

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top